Ikena Oncology, Inc. is a high-risk pharmaceutical company based in the United States. They focus on developing precision therapies for cancer patients by targeting nodes of cancer growth, spread, and therapeutic resistance in the Hippo and RAS onco-signaling network. Their targeted oncology product candidate, IK-930, is an oral small-molecule inhibitor of TEAD, a transcription factor in the Hippo signaling pathway. Ikena Oncology also has other product candidates, including IK-175 and IK-595. With an ESG score of 32.4, Ikena Oncology is dedicated to environmental sustainability and governance in its operations.